PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33895784-0	2021	Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.	ruxolitinib	24-35	cytokine receptor like factor 2	Homo sapiens	67-72	
34591931-8	2021	Moreover, differences in sensitivity of two CRLF2-drivenBCP-ALL cell lines to ruxolitinib were also seen.	ruxolitinib	78-89	cytokine receptor like factor 2	Homo sapiens	44-49	
34505882-8	2021	In summary, IKZF1 deletion and a switch from cytokine dependence to activated BCR-like signaling phenotype represent putative mechanisms of ruxolitinib resistance in this case, recapitulating preclinical data on resistance to JAK inhibition in CRLF2-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.	ruxolitinib	140-151	cytokine receptor like factor 2	Homo sapiens	244-249	
33895784-7	2021	Based on these findings, we conducted preclinical in vivo drug testing and demonstrated that ruxolitinib enhanced the in vivo efficacy of an induction-type regimen consisting of vincristine, dexamethasone, and L-asparaginase in 2/3 CRLF2-rearranged Ph-like ALL xenografts.	ruxolitinib	93-104	cytokine receptor like factor 2	Homo sapiens	232-237	
33895784-8	2021	Overall, our findings support evaluating the addition of ruxolitinib to conventional induction regimens for the treatment of CRLF2-rearranged Ph-like ALL.	ruxolitinib	57-68	cytokine receptor like factor 2	Homo sapiens	125-130	
27449287-4	2016	Of note, CRLF2 over-expression was associated with poor prognosis in the high risk (HR) subgroup where CRLF2-high patients were more frequently allocated.Interestingly, although in T-ALL CRLF2 protein was localized mainly in the cytoplasm, in CRLF2-high blasts we found a trend towards a stronger TSLP-induced pSTAT5 response, sensitive to the JAK inhibitor Ruxolitinib.In conclusion, CRLF2 over-expression is a poor prognostic marker identifying a subset of HR T-ALL patients that could benefit from alternative therapy, potentially targeting the CRLF2 pathway.	ruxolitinib	358-369	cytokine receptor like factor 2	Homo sapiens	9-14	
27777238-7	2017	Combined gedatolisib and ruxolitinib treatment of CRLF2/JAK-mutant models more effectively inhibited ALL proliferation than either inhibitor alone (P < .001) and further enhanced survival.	ruxolitinib	25-36	cytokine receptor like factor 2	Homo sapiens	50-55	
25976292-1	2015	BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations.	ruxolitinib	12-23	cytokine receptor like factor 2	Homo sapiens	92-97